SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-053547
Filing Date
2023-10-16
Accepted
2023-10-16 16:33:03
Documents
12
Period of Report
2023-10-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K impl-20231010.htm   iXBRL 8-K 58369
  Complete submission text file 0000950170-23-053547.txt   188938

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20231010_pre.xml EX-101.PRE 12037
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20231010_lab.xml EX-101.LAB 18778
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20231010.xsd EX-101.SCH 2459
6 EXTRACTED XBRL INSTANCE DOCUMENT impl-20231010_htm.xml XML 4892
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 231327668
SIC: 2834 Pharmaceutical Preparations